Q-omics provides the consensus-scored ASMT profile across patient tissues and cancer cell-line models. ASMT expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, ASMT is differentially expressed in 9, with the highest sampling consensus in KIRC. Additionally, ASMT RNA expression shows 9,677 significant gene co-expression associations, with the highest sampling consensus in KIRP. Together, these results highlight BLCA, KIRC, and KIRP as cancer lineages where ASMT shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ASMT — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ASMT survival associations across molecular data types. ASMT RNA expression shows survival associations in the most cancer types (24), followed by mutation status (9). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ASMT RNA expression–survival associations across cancer types. High ASMT expression shows favorable associations in BLCA, SKCM, READ, BRCA, SCLC and HNSC. The BLCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify BLCA as the clearest survival context for ASMT RNA expression.
This table summarizes ASMT tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for ASMT. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ASMT shows lower tumor expression in UCEC, BRCA and BLCA and higher tumor expression in KIRC, LIHC and CHOL. The KIRC box plot shows higher ASMT RNA expression in tumor versus normal tissue (log2 FC = +0.110, t-test p < 0.001).
This table shows molecular features associated with ASMT in patient tissues and cancer cell lines. In patient samples, ASMT shows the broadest associations at the RNA and protein expression levels, with KIRP recurring as the lineage with the largest associated feature set. In cancer cell lines, ASMT RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and SKIN.
